## Hugh J Willison

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5266086/publications.pdf

Version: 2024-02-01

		26630	24258
157	13,067	56	110
papers	citations	h-index	g-index
170	170	170	9512
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The role of gangliosides in the organisation of the node of Ranvier examined in glycosyltransferase transgenic mice. Journal of Anatomy, 2022, 241, 1259-1271.	1.5	7
2	Detection of Autoantibodies Using Combinatorial Glycolipid Microarrays. Methods in Molecular Biology, 2022, 2460, 183-191.	0.9	1
3	Post-Infectious Autoimmunity in the Central (CNS) and Peripheral (PNS) Nervous Systems: An African Perspective. Frontiers in Immunology, 2022, 13, 833548.	4.8	7
4	Predicting Outcome in Guillain-Barré Syndrome. Neurology, 2022, 98, .	1.1	22
5	SARM1 Depletion Slows Axon Degeneration in a CNS Model of Neurotropic Viral Infection. Frontiers in Molecular Neuroscience, 2022, 15, 860410.	2.9	8
6	Real time imaging of intra-axonal calcium flux in an explant mouse model of axonal Guillain-Barré syndrome. Experimental Neurology, 2022, 355, 114127.	4.1	5
7	Schwann cell nodal membrane disruption triggers bystander axonal degeneration in a Guillain-Barré syndrome mouse model. Journal of Clinical Investigation, 2022, 132, .	8.2	15
8	Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain, 2021, 144, 682-693.	7.6	221
9	COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations. Brain, 2021, 144, 357-360.	7.6	77
10	Guillain-Barré syndrome during the Zika virus outbreak in Northeast Brazil: An observational cohort study. Journal of the Neurological Sciences, 2021, 420, 117272.	0.6	24
11	Guillain-Barré Syndrome Outbreak in Peru 2019 Associated With <i>Campylobacter jejuni</i> Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	20
12	Reply: Guillain-Barré syndrome, SARS-CoV-2 and molecular mimicry <i>and </i> Ongoing challenges in unravelling the association between COVID-19 and Guillain-Barré syndrome <i>and </i> Unclear association between COVID-19 and Guillain-Barré syndrome <i>and </i> Currently available data regarding the potential association between COVID-19 and Guillain-Barré syndrome. Brain, 2021, 144,	7.6	4
13	e47-e47.  Neuronally expressed aâ€series gangliosides are sufficient to prevent the lethal ageâ€dependent phenotype in GM3â€only expressing mice. Journal of Neurochemistry, 2021, 158, 217-232.	3.9	2
14	Oligodendrocytes are susceptible to Zika virus infection in a mouse model of perinatal exposure: Implications for CNS complications. Glia, 2021, 69, 2023-2036.	4.9	17
15	A novel MT-CO2 variant causing cerebellar ataxia and neuropathy: The role of muscle biopsy in diagnosis and defining pathogenicity. Neuromuscular Disorders, 2021, 31, 1186-1193.	0.6	5
16	Guillain-Barr $\tilde{A}$ © syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain, 2021, 144, 3392-3404.	7.6	39
17	Zika Virus Infection Leads to Demyelination and Axonal Injury in Mature CNS Cultures. Viruses, 2021, 13, 91.	3.3	17
18	Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 311-318.	1.9	21

#	Article	IF	Citations
19	BAF45b Is Required for Efficient Zika Virus Infection of HAP1 Cells. Viruses, 2021, 13, 2007.	3.3	2
20	Serum antiâ€GM2 and antiâ€GalNAcâ€GD1a lgG antibodies are biomarkers for acute canine polyradiculoneuritis. Journal of Small Animal Practice, 2021, , .	1.2	4
21	The legacy of ZikaPLAN: a transnational research consortium addressing Zika. Global Health Action, 2021, 14, 2008139.	1.9	5
22	Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study. Lancet Neurology, The, 2020, 19, 826-839.	10.2	68
23	Perisynaptic Schwann cells phagocytose nerve terminal debris in a mouse model of <scp>Guillainâ€Barré</scp> syndrome. Journal of the Peripheral Nervous System, 2020, 25, 143-151.	3.1	21
24	The Use of Myelinating Cultures as a Screen of Glycomolecules for CNS Repair. Biology, 2019, 8, 52.	2.8	3
25	ZikaPLAN: addressing the knowledge gaps and working towards a research preparedness network in the Americas. Global Health Action, 2019, 12, 1666566.	1.9	13
26	Diagnosis and management of Guillain–Barré syndrome in ten steps. Nature Reviews Neurology, 2019, 15, 671-683.	10.1	463
27	Current treatment practice of Guillain-Barré syndrome. Neurology, 2019, 93, e59-e76.	1.1	57
28	MyelinJ: an ImageJ macro for high throughput analysis of myelinating cultures. Bioinformatics, 2019, 35, 4528-4530.	4.1	30
29	Low sulfated heparins target multiple proteins for central nervous system repair. Glia, 2019, 67, 668-687.	4.9	18
30	Glial Sulfatides and Neuronal Complex Gangliosides Are Functionally Interdependent in Maintaining Myelinating Axon Integrity. Journal of Neuroscience, 2019, 39, 63-77.	3.6	30
31	The elusive diagnosis of sensory neuronopathy. Arquivos De Neuro-Psiquiatria, 2019, 77, 449-450.	0.8	0
32	Zika virus infection in the returning traveller: what every neurologist should know. Practical Neurology, 2018, 18, 271-277.	1.1	25
33	Heparanase attenuates axon degeneration following sciatic nerve transection. Scientific Reports, 2018, 8, 5219.	3.3	8
34	Nodes, paranodes and neuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 61-71.	1.9	60
35	Regional variation of Guillain-Barré syndrome. Brain, 2018, 141, 2866-2877.	7.6	190
36	Anti-ganglioside Antibodies in Peripheral Nerve Pathology. Methods in Molecular Biology, 2018, 1804, 173-188.	0.9	8

#	Article	IF	CITATIONS
37	Autoimmune Neurological Conditions Associated With Zika Virus Infection. Frontiers in Molecular Neuroscience, 2018, 11, 116.	2.9	46
38	Differential binding patterns of anti-sulfatide antibodies to glial membranes. Journal of Neuroimmunology, 2018, 323, 28-35.	2.3	7
39	Gangliosides and Autoimmune Peripheral Nerve Diseases. Progress in Molecular Biology and Translational Science, 2018, 156, 355-382.	1.7	19
40	Guillain-Barré syndrome: surveillance and cost of treatment strategies – Authors' reply. Lancet, The, 2017, 389, 253-254.	13.7	11
41	International Guillainâ∈Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillainâ∈Barré syndrome. Journal of the Peripheral Nervous System, 2017, 22, 68-76.	3.1	89
42	Co-cultures with stem cell-derived human sensory neurons reveal regulators of peripheral myelination. Brain, 2017, 140, 898-913.	7.6	92
43	Zika virus tropism and interactions in myelinating neural cell cultures: CNS cells and myelin are preferentially affected. Acta Neuropathologica Communications, 2017, 5, 50.	5.2	56
44	Inhibition of complement in Guillainâ€Barré syndrome: the <scp>ICAâ€GBS</scp> study. Journal of the Peripheral Nervous System, 2017, 22, 4-12.	3.1	70
45	ZikaPLAN: Zika Preparedness Latin American Network. Global Health Action, 2017, 10, 1398485.	1.9	25
46	Autoantibodies to Glycolipids in Peripheral Neuropathy. , 2016, , 961-965.		0
46	Autoantibodies to Glycolipids in Peripheral Neuropathy. , 2016, , 961-965.  Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies. Current Opinion in Neurology, 2016, 29, 572-580.	3.6	0
	Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated	3.6 13.7	
47	Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies. Current Opinion in Neurology, 2016, 29, 572-580.  Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a		33
47	Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies. Current Opinion in Neurology, 2016, 29, 572-580.  Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet, The, 2016, 387, 1531-1539.	13.7	1,913
47 48 49	Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies. Current Opinion in Neurology, 2016, 29, 572-580.  Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet, The, 2016, 387, 1531-1539.  Guillain-Barré syndrome. Lancet, The, 2016, 388, 717-727.  Anti-ganglioside antibodies are removed from circulation in mice by neuronal endocytosis. Brain, 2016,	13.7	1,913 1,076
47 48 49 50	Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies. Current Opinion in Neurology, 2016, 29, 572-580.  Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet, The, 2016, 387, 1531-1539.  Guillain-Barré syndrome. Lancet, The, 2016, 388, 717-727.  Anti-ganglioside antibodies are removed from circulation in mice by neuronal endocytosis. Brain, 2016, 139, 1657-1665.	13.7 13.7 7.6	1,913 1,076 27
47 48 49 50	Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies. Current Opinion in Neurology, 2016, 29, 572-580.  Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet, The, 2016, 387, 1531-1539.  Guillain-Barré syndrome. Lancet, The, 2016, 388, 717-727.  Anti-ganglioside antibodies are removed from circulation in mice by neuronal endocytosis. Brain, 2016, 139, 1657-1665.  C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy. Acta Neuropathologica Communications, 2016, 4, 23.  Asymptomatic dengue infection may trigger Guillainâ€Barré syndrome. Journal of the Peripheral	13.7 13.7 7.6	33 1,913 1,076 27

#	Article	IF	CITATIONS
55	Guillain-Barr $ ilde{A}$ © syndrome in the 100 years since its description by Guillain, Barr $ ilde{A}$ © and Strohl. Brain, 2016, 139, 3041-3047.	7.6	22
56	Neuroinflammation in the peripheral nerve: Cause, modulator, or bystander in peripheral neuropathies?. Glia, 2016, 64, 475-486.	4.9	73
57	The Diagnostic Utility of Determining Anti-GM1: GalC Complex Antibodies in Multifocal Motor Neuropathy: A Validation Study. Journal of Neuromuscular Diseases, 2015, 2, 157-165.	2.6	8
58	Prospective study comparing enzymeâ€linked immunosorbent assay and glycoarray assay to detect antiglycolipid antibodies in a routine diagnostic neuroimmunology laboratory setting. Clinical and Experimental Neuroimmunology, 2015, 6, 175-182.	1.0	5
59	Improving the detection of IgM antibodies against glycolipids complexes of GM1 and Galactocerebroside in Multifocal Motor Neuropathy using glycoarray and ELISA assays. Journal of Neuroimmunology, 2015, 278, 159-161.	2.3	23
60	Progress in inflammatory neuropathy â€"the legacy of Dr Jack Griffin. Nature Reviews Neurology, 2015, 11, 646-650.	10.1	8
61	Anti-GQ1b ganglioside positive Miller Fisher syndrome – evidence of paranodal pathology on nerve biopsy. Journal of Neuromuscular Diseases, 2014, 1, 191-195.	2.6	9
62	The preâ€synaptic motor nerve terminal as a site for antibodyâ€mediated neurotoxicity in autoimmune neuropathies and synaptopathies. Journal of Anatomy, 2014, 224, 36-44.	1.5	16
63	Glycoconjugates and Neuroimmunological Diseases. Advances in Neurobiology, 2014, 9, 543-566.	1.8	9
64	Neuronal Expression of GalNAc Transferase Is Sufficient to Prevent the Age-Related Neurodegenerative Phenotype of Complex Ganglioside-Deficient Mice. Journal of Neuroscience, 2014, 34, 880-891.	3.6	42
65	The application of glycosphingolipid arrays to autoantibody detection in neuroimmunological disorders. Current Opinion in Chemical Biology, 2014, 18, 78-86.	6.1	25
66	Ranvier revisited. Neurology, 2014, 83, 106-108.	1.1	15
67	Antibodies to GM1: galactocerebroside complexes in multifocal motor neuropathy: it takes two to tango. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 715-715.	1.9	2
68	Commentary. Journal of Neurosciences in Rural Practice, 2014, 5, 65-7.	0.8	0
69	Anti-GQ1b ganglioside positive Miller Fisher syndrome - evidence of paranodal pathology on nerve biopsy. Journal of Neuromuscular Diseases, 2014, 1, 191-195.	2.6	3
70	Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy. European Journal of Neurology, 2013, 20, 62-70.	3.3	50
71	Glycolipid antigens and autoantibodies in autoimmune neuropathies. Trends in Immunology, 2013, 34, 453-459.	6.8	56
72	Antiâ€ <scp>GM2</scp> ganglioside antibodies are a biomarker forÂacute canine polyradiculoneuritis. Journal of the Peripheral Nervous System, 2013, 18, 75-88.	3.1	27

#	Article	IF	Citations
73	The effects of age and ganglioside composition on the rate of motor nerve terminal regeneration following antibodyâ€mediated injury in mice. Synapse, 2013, 67, 382-389.	1.2	4
74	Antibodies to Heteromeric Glycolipid Complexes in Guillain-Barré Syndrome. PLoS ONE, 2013, 8, e82337.	2.5	60
75	Sialoadhesin Promotes Rapid Proinflammatory and Type I IFN Responses to a Sialylated Pathogen, <i>Campylobacter jejuni</i> Journal of Immunology, 2012, 189, 2414-2422.	0.8	71
76	Autoantibodies in immune-mediated neuropathies. Current Opinion in Neurology, 2012, 25, 550-555.	3.6	27
77	Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain, 2012, 135, 1819-1833.	7.6	123
78	The translation of the pathological findings described in humans to experimental models of acute motor axonal neuropathy. Journal of the Peripheral Nervous System, 2012, 17, 3-8.	3.1	14
79	Motor nerve terminal destruction and regeneration following anti-ganglioside antibody and complement-mediated injury: An in and ex vivo imaging study in the mouse. Experimental Neurology, 2012, 233, 836-848.	4.1	27
80	Combinatorial Glycoarray. Methods in Molecular Biology, 2012, 808, 413-423.	0.9	23
81	Anti-ganglioside antibody internalization attenuates motor nerve terminal injury in a mouse model of acute motor axonal neuropathy. Journal of Clinical Investigation, 2012, 122, 1037-1051.	8.2	42
82	Sialylation of Campylobacter jejuni Lipo-Oligosaccharides: Impact on Phagocytosis and Cytokine Production in Mice. PLoS ONE, 2012, 7, e34416.	2.5	24
83	Neuromuscular synaptic transmission in aged ganglioside-deficient mice. Neurobiology of Aging, 2011, 32, 157-167.	3.1	16
84	Neuropathophysiological potential of Guillain-Barr $\tilde{A}$ © syndrome anti-ganglioside-complex antibodies at mouse motor nerve terminals. Clinical and Experimental Neuroimmunology, 2011, 2, 59-67.	1.0	11
85	Biomarkers in experimental models of antibodyâ€mediated neuropathies. Journal of the Peripheral Nervous System, 2011, 16, 60-62.	3.1	14
86	An open label clinical trial of complement inhibition in multifocal motor neuropathy. Journal of the Peripheral Nervous System, 2011, 16, 84-91.	3.1	80
87	Lipid arrays identify myelin-derived lipids and lipid complexes as prominent targets for oligoclonal band antibodies in multiple sclerosis. Journal of Neuroimmunology, 2011, 238, 87-95.	2.3	66
88	Reply: Neurofascin as target of autoantibodies in Guillain-Barre syndrome. Brain, 2011, 134, e174-e174.	7.6	0
89	Heteromeric glycolipid complexes as modulators of autoantibody and lectin binding. Progress in Lipid Research, 2010, 49, 87-95.	11.6	23
90	Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain, 2010, 133, 1944-1960.	7.6	149

#	Article	IF	Citations
91	Immunolocalization of GQ1b and Related Gangliosides in Human Extraocular Neuromuscular Junctions and Muscle Spindles. , 2009, 50, 3226.		131
92	Pathophysiological actions of neuropathyâ€related antiâ€ganglioside antibodies at the neuromuscular junction. Journal of Physiology, 2009, 587, 3979-3999.	2.9	77
93	Analysis of lectin binding to glycolipid complexes using combinatorial glycoarrays. Glycobiology, 2009, 19, 789-796.	2.5	57
94	The neuropathic potential of anti-GM1 autoantibodies is regulated by the local glycolipid environment in mice. Journal of Clinical Investigation, 2009, 119, 595-610.	8.2	100
95	Subclass IgG to motor gangliosides related to infection and clinical course in Guillain–Barré syndrome. Journal of Neuroimmunology, 2008, 194, 181-190.	2.3	55
96	The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain–Barré syndrome. Journal of Neuroimmunology, 2008, 201-202, 172-182.	2.3	59
97	Neuromuscular synaptic function in mice lacking major subsets of gangliosides. Neuroscience, 2008, 156, 885-897.	2.3	24
98	Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain, 2008, 131, 1197-1208.	7.6	202
99	Ganglioside antibodies and neuropathies. Current Opinion in Neurology, 2008, 21, 540-546.	3.6	27
100	Solid phase immunoadsorption for therapeutic and analytical studies on neuropathy-associated anti-GM1 antibodies. Glycobiology, 2007, 17, 294-303.	2.5	38
101	Sulfatide binding properties of murine and human antiganglioside antibodies. Glycobiology, 2007, 17, 1156-1166.	2.5	8
102	Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. The Cochrane Library, 2007, , CD004761.	2.8	72
103	Basic and clinical aspects of autoimmune disorders in peripheral nerves. Acta Neurologica Scandinavica, 2006, 113, 14-18.	2.1	36
104	The immunobiology of Guillain-Barre syndromes. Journal of the Peripheral Nervous System, 2005, 10, 94-112.	3.1	167
105	Characterisation of the immunoglobulin variable region gene usage encoding the murine anti-ganglioside antibody repertoire. Journal of Neuroimmunology, 2005, 165, 92-103.	2.3	34
106	Anti-disialosyl antibodies mediate selective neuronal or Schwann cell injury at mouse neuromuscular junctions. Glia, 2005, 52, 177-189.	4.9	57
107	Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Annals of Neurology, 2005, 58, 203-210.	5.3	100
108	Ganglioside complexes: new autoantibody targets in Guillain–Barré syndromes. Nature Clinical Practice Neurology, 2005, 1, 2-3.	2.5	31

#	Article	IF	Citations
109	Overexpression of GD1a Ganglioside Sensitizes Motor Nerve Terminals to Anti-GD1a Antibody-Mediated Injury in a Model of Acute Motor Axonal Neuropathy. Journal of Neuroscience, 2005, 25, 1620-1628.	3.6	111
110	Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain, 2004, 127, 2109-2123.	7.6	122
111	Innate murine B cells produce anti-disialosyl antibodies reactive with Campylobacter jejuni LPS and gangliosides that are polyreactive and encoded by a restricted set of unmutated V genes. Journal of Neuroimmunology, 2004, 152, 98-111.	2.3	29
112	CLINICAL EVALUATION AND INVESTIGATION OF NEUROPATHY. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 3ii-8.	1.9	33
113	Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury. Brain, 2003, 126, 2497-2509.	7.6	81
114	Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera. Brain, 2003, 127, 680-691.	7.6	57
115	Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain, 2003, 126, 2220-2234.	7.6	85
116	Infectious causes of acute flaccid paralysis. Current Opinion in Infectious Diseases, 2003, 16, 375-381.	3.1	105
117	Peripheral neuropathies and anti-glycolipid antibodies. Brain, 2002, 125, 2591-2625.	7.6	679
118	Tolerance to Self Gangliosides Is the Major Factor Restricting the Antibody Response to Lipopolysaccharide Core Oligosaccharides in Campylobacter jejuni Strains Associated with Guillain-Barrel•Syndrome. Infection and Immunity, 2002, 70, 5008-5018.	2.2	103
119	Multifocal Motor Neuropathy. Practical Neurology, 2002, 2, 298-301.	1.1	2
120	Complex Gangliosides at the Neuromuscular Junction Are Membrane Receptors for Autoantibodies and Botulinum Neurotoxin But Redundant for Normal Synaptic Function. Journal of Neuroscience, 2002, 22, 6876-6884.	3 <b>.</b> 6	98
121	Complex gangliosides as autoantibody targets at the neuromuscular junction in Miller Fisher syndrome: a current perspective. Neurochemical Research, 2002, 27, 697-709.	3.3	34
122	Anti-glycolipid antibodies in the diagnosis of autoimmune neuropathies. Revue Neurologique, 2002, 158, S16-20.	1.5	6
123	The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain, 2001, 124, 1968-1977.	7.6	254
124	Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of Neurology, 2001, 50, 195-201.	<b>5.</b> 3	577
125	Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain, 2001, 124, 893-906.	7.6	166
126	Long-term clinical and neurophysiological follow-up of patients with peripheral, neuropathy associated with benign monoclonal gammopathy. Muscle and Nerve, 2000, 23, 164-174.	2,2	58

#	Article	IF	CITATIONS
127	Anti-GQ1b antibodies and evoked acetylcholine release at mouse motor endplates. Muscle and Nerve, 2000, 23, 1035-1043.	2.2	32
128	EFNS Task Force Report: a questionnaire-based survey on the service provision and quality assurance for determination of diagnostic autoantibody tests in European neuroimmunology centres. European Journal of Neurology, 2000, 7, 625-628.	3.3	16
129	Peripheral Neuropathy Associated with Anti-GM2 Ganglioside Antibodies: Clinical and Immunopathological Studies. Autoimmunity, 2000, 32, 133-144.	2.6	46
130	Antiâ€GQ1b antibodies and evoked acetylcholine release at mouse motor endplates. Muscle and Nerve, 2000, 23, 1035-1043.	2.2	1
131	Monoclonal antibodies raised against Guillain-Barré syndrome–associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. Journal of Clinical Investigation, 1999, 104, 697-708.	8.2	198
132	Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro. Brain, 1999, 122, 807-816.	7.6	114
133	Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. European Journal of Neurology, 1999, 6, 71-77.	3.3	121
134	Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barr� syndrome. Annals of Neurology, 1999, 45, 168-173.	5.3	308
135	Miller Fisher anti-GQ1b antibodies: ?-Latrotoxin-like effects on motor end plates. Annals of Neurology, 1999, 45, 189-199.	5.3	203
136	Mapping immunoreactive epitopes in the human peripheral nervous system using human monoclonal anti-GM1 ganglioside antibodies. Acta Neuropathologica, 1998, 95, 605-616.	7.7	51
137	Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after campylobacter infection. Neurology, 1997, 48, 717-724.	1.1	183
138	Mechanisms of Action of Antiâ€GM <sub>1</sub> and Antiâ€GQ <sub>1b</sub> Ganglioside Antibodies in Guillainâ€Barré Syndrome. Journal of Infectious Diseases, 1997, 176, S144-S149.	4.0	37
139	A somatically mutated human antiganglioside $\lg M$ antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18 Journal of Clinical Investigation, 1996, 97, 1155-1164.	8.2	87
140	Autoimmune responses in peripheral nerve. Seminars in Immunopathology, 1996, 18, 97-123.	4.0	46
141	Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides Journal of Neurology, Neurosurgery and Psychiatry, 1996, 61, 649-651.	1.9	104
142	Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Annals of Neurology, 1995, 38, 111-118.	5.3	105
143	Analysis of anti-GM1 ganglioside IgM antibodies cloned from motor neuropathy patients demonstrates diverse V region gene usage with extensive somatic mutation. Journal of Immunology, 1995, 155, 3049-59.	0.8	43
144	Cloning of human anti-GM1 antibodies from motor neuropathy patients. Annals of Neurology, 1994, 35, 471-478.	5.3	51

#	Article	IF	CITATIONS
145	Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller fisher syndrome. Journal of Neuroimmunology, 1994, 50, 159-165.	2.3	115
146	Involvement of cation channels in autoimmune disease. Biochemical Society Transactions, 1994, 22, 488-491.	3.4	1
147	Acute ataxic neuropathy with crossâ€reactive antibodies to GD ⟨sub⟩lb⟨ sub⟩ and GD ⟨sub⟩3⟨ sub⟩ gangliosides. Neurology, 1994, 44, 2395-2395.	1.1	59
148	Gangliosides and bacterial toxins in Guillain-Barr $\tilde{A}$ © syndrome. Journal of Neuroimmunology, 1993, 46, 105-112.	2.3	74
149	Antiglycolipid antibodies, immunoglobulins and paraproteins in motor neuron disease: a population based case-control study. Journal of the Neurological Sciences, 1993, 114, 209-215.	0.6	31
150	Peripheral neuropathy associated with monoclonal IgM anti-Pr2 cold agglutinins Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 1178-1183.	1.9	67
151	Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 204-206.	1.9	232
152	Acute motor neuropathy with antibodies to GM1 ganglioside. Journal of Neurology, 1991, 238, 447-451.	3.6	66
153	Serum antibodies to gangliosides in guillain-barré syndrome. Annals of Neurology, 1988, 23, 440-447.	5.3	257
154	Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies. Muscle and Nerve, 1988, 11, 1169-1176.	2.2	134
155	Use of Anti-Nerve Antibodies. , 0, , 87-93.		0
156	Diretrizes Baseadas em Evidências Diagnóstico e manejo da SÃndrome de Guillain–Barré em dez etapas. Revista Neurociencias, 0, 29, 1-52.	0.0	0
157	Diagnosis and management of Guillain–Barré syndrome in ten steps. , 0, .		1